

Table 2:**Data Sources for exposure and outcomes**

Data	Data Source	Population Ancestry	Sample size	Exposure definition	Adjustments
Genetic variants in or near IL-6R associated with variation in CRP	CHARGE Inflammation Working Group ¹³	European	204,402	Change in natural log transformed CRP (mg/L) per copy increment of the effect allele	Age, sex, population structure. Estimates scaled for the effect of Tocilizumab (8 mg/kg) on CRP levels between 4 – 24 weeks after administration.
Blood urea nitrogen (BUN)	Chronic Kidney Disease Genetics Consortium meta-analysis (n=33 studies) ¹⁴	Trans-ancestry	416,178	Change in BUN per copy increment of effect allele	Age, sex, population structure
Estimated glomerular filtration rate (eGFR)	Chronic Kidney Disease Genetics Consortium meta-analysis (n=61 studies) ¹⁴	Trans-ancestry	765,348	Change in log eGFR per copy increment of effect allele	Age, sex, population structure
Chronic Kidney Disease Binary outcome eGFR > 60 ml min ⁻¹ per 1.73 m ² .	Chronic Kidney Disease Genetics Consortium meta-analysis (n=30 studies) ¹⁴	Trans-ancestry	64,164 cases 561,055 controls	Log odds ratio for CKD per copy increment of effect allele	Age, sex, population structure

Table 2 describes the source, population ancestry, sample size and exposure definitions for the GWAS studies used in the present MR analysis.